First case report of intrathecal panitumumab for treatment of meningeal carcinomatousis in an EGFR mutant lung adenocarcinoma patient

Lung Cancer. 2013 Apr;80(1):113-4. doi: 10.1016/j.lungcan.2012.12.016. Epub 2013 Jan 23.

Authors

Antoine Hollebecque, Antonin Levy, Sophie Broutin, François Lemare, Anas Gazzah, Romain Desmaris, Catherine Chenailler, Matthieu Elbaum, Benjamin Besse, Angelo Paci, Jean-Charles Soria

PMID: 23352031
DOI: 10.1016/j.lungcan.2012.12.016

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Adenocarcinoma / drug therapy*
Adenocarcinoma / genetics
Adenocarcinoma / pathology
Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / therapeutic use*
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / therapeutic use
ErbB Receptors / antagonists & inhibitors*
ErbB Receptors / genetics
Humans
Injections, Spinal
Lung Neoplasms / drug therapy*
Lung Neoplasms / genetics
Lung Neoplasms / pathology
Male
Meningeal Carcinomatosis / drug therapy*
Meningeal Carcinomatosis / genetics
Meningeal Carcinomatosis / secondary
Middle Aged
Mutation
Panitumumab
Treatment Outcome

Substances

Antibodies, Monoclonal
Antineoplastic Agents
Panitumumab
EGFR protein, human
ErbB Receptors